MAP2K7 and ovarian cancer: A systematic review investigating the potential of Ras/Raf/MAPK(MEK)/ERK signaling pathway inhibitors in ovarian cancer showed a clinical benefit rate (CBR) of 63% and an overall response rate (ORR) of 13% in patients with ovarian cancer treated with MAPK inhibitors.